Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response

November 17, 2023

Non-V600 BRAF mutated melanomas, compared to those with BRAF V600 mutations or BRAF WT tumors, had higher levels of immune cell infiltration, increased tumor mutation burden (TMB), and elevated expression of immune checkpoint and T cell exhaustion markers, indicating a potentially favorable response to combination immune checkpoint inhibitors (ICPIs).